MEA Internal Neurostimulation Devices Market - Industry Trends Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143145
- Pages: 225
-
Format:
Short Description:
Middle East and Africa Internal Neurostimulation Devices Market, By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider), Country (South Africa, UAE, Egypt, Saudi Arabia, Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
An internal neurostimulation device is a surgically placed device. It delivers mild electrical signals to the epidural space near your spine through one or more thin wires called leads. Neurostimulation provides pain relief by disrupting the pain signals traveling between the spinal cord and the brain.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
Market Segmentation:
The Middle East and Africa internal neurostimulation devices market is categorized into product type and distribution channel.
On the basis of product type, the Middle East and Africa internal neurostimulation devices market is segmented into spinal cord stimulation (SCS), deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation
On the basis of distribution channel, the Middle East and Africa internal neurostimulation devices market is segmented into direct tender and third party service provider
Market Players:
Some key market players operating in the Middle East and Africa internal neurostimulation devices market are listed below:
Medtronic
LivaNova PLC
Abbott
Microsemi (a subsidiary of Microchip Technology Inc.)
Boston Scientific Corporation
BlueWind Medical
Valencia Technologies
Sequana Medical NV
TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF MIDDLE EAST & AFRICA INTERNAL NEUROSTIMULATION DEVICES MARKET 66
1.4 CURRENCY AND PRICING 69
1.5 LIMITATION 69
1.6 MARKETS COVERED 69
2 MARKET SEGMENTATION 74
2.1 MARKETS COVERED 74
2.2 GEOGRAPHIC SCOPE 75
2.3 YEARS CONSIDERED FOR THE STUDY 76
2.4 CURRENCY AND PRICING 76
2.5 RESEARCH METHODOLOGY 77
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.7 DBMR MARKET POSITION GRID 81
2.8 THE CATEGORY VS TIME GRID 83
2.9 SECONDARY SOURCES 84
2.10 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 87
4.1 PESTEL 88
4.2 PORTER'S FIVE FORCES MODEL 89
4.3 PIPELINE ANALYSIS FOR INTERNAL NEUROSTIMULATION DEVICES MARKET 90
5 REGULATIONS OF MIDDLE EAST & AFRICA INTERNAL NEUROSTIMULATION DEVICES MARKET 92
6 EPIDEMIOLOGY OF DISEASES 94
6.1 INCIDENCE OF ISCHEMIA 94
6.2 INCIDENCE OF PARKINSON'S DISEASE 94
6.3 INCIDENCE OF FAILED BACK SYNDROME 95
6.4 INCIDENCE OF TREMOR 95
6.5 INCIDENCE OF DEPRESSION 96
6.6 INCIDENCE OF URINE INCONTINENCE 96
6.7 INCIDENCE OF FECAL INCONTINENCE 97
6.8 INCIDENCE RATE OF EPILEPSY 97
6.9 INCIDENCE OF GASTROPARESIS 98
6.10 PREVALENCE OF OBESITY 99
7 EPIDEMIOLOGY OF NEUROSTIMULATION PROCEDURES 101
7.1 NUMBER OF SPINAL CORD STIMULATION (SCS) PROCEDURES 101
7.1.1 NUMBER OF TEST PROCEDURES 101
7.1.2 NUMBER OF IMPLANTATION PROCEDURES 101
7.2 NUMBER OF DEEP BRAIN STIMULATION PROCEDURES 101
7.3 NUMBER OF VAGUS NERVE STIMULATION PROCEDURES 101
7.4 NUMBER OF SACRAL NEVER STIMULATION PROCEDURES 102
7.5 NUMBER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) PROCEDURES 102
7.6 NUMBER OF INTERMITTENT THETA BURST STIMULATION (ITBS) PROCEDURES 102
7.7 NUMBER OF TRANSCRANIAL DIRECT ELECTRICAL STIMULATION (TDCS) PROCEDURES 103
8 MARKET OVERVIEW 104
8.1 DRIVERS 106
8.1.1 RISE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS 106
8.1.2 DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY 107
8.1.3 INCREASED FUNDING FOR THE NEUROSTIMULATION DEVICES 107
8.1.4 TECHNOLOGICAL ADVANCEMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 107
8.1.5 RISE IN PRODUCT APPROVALS 108
8.2 RESTRAINTS 109
8.2.1 RISE IN COST OF THE DEEP BRAIN STIMULATION DEVICES 109
8.2.2 RISKS NOTICED WHILE USING THE INTERNAL NEUROSTIMULATION DEVICES 109
8.2.3 RISE IN PRODUCT RECALL 109
8.2.4 AVAILABILITY OF ALTERNATE IMAGING DIAGNOSTIC DEVICES 110
8.3 OPPORTUNITIES 110
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 110
8.3.2 RECENT PRODUCT DEVELOPMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 111
8.3.3 DEMAND FOR MINIMALLY INVASIVE SURGERY 111
8.4 CHALLENGES 112
8.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES 112
8.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS 112
9 MIDDLE EAST & AFRICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE 113
9.1 OVERVIEW 114
9.2 SPINAL CORD STIMULATION 117
9.2.1 SPINAL CORD STIMULATION, BY TYPE 118
9.2.1.1 BATTERY 118
9.2.1.1.1 RECHARGEABLE 119
9.2.1.1.2 NON-RECHARGEABLE 119
9.2.1.2 LEAD 119
9.2.1.2.1 PERCUTANEOUS 120
9.2.1.2.2 PADDLE 120
9.2.2 SPINAL CORD STIMULATION, BY APPLICATION 120
9.2.2.1 ISCHEMIA 120
9.2.2.2 CHRONIC LOW BACK PAIN (CLBP) 120
9.2.2.3 DIABETIC NEUROPATHY 121
9.2.2.4 FAILED BACK SYNDROME 121
9.3 DEEP BRAIN STIMULATION 121
9.3.1 DEEP BRAIN STIMULATION, BY TYPE 122
9.3.1.1 SINGLE CHANNEL DEEP BRAIN STIMULATOR 123
9.3.1.2 DOUBLE CHANNEL DEEP BRAIN STIMULATOR 123
9.3.1.3 BATTERY 123
9.3.1.3.1 RECHARGEABLE 124
9.3.1.3.2 NON-RECHARGEABLE 124
9.3.1.4 LEAD 124
9.3.2 DEEP BRAIN STIMULATION, BY APPLICATION 124
9.3.2.1 PARKINSONS DISEASE 125
9.3.2.2 TREMOR 125
9.3.2.3 DEPRESSION 125
9.4 SACRAL NERVE STIMULATION 125
9.4.1 SACRAL NERVE STIMULATION, BY TYPE 126
9.4.1.1 BATTERY 127
9.4.1.2 LEAD 127
9.5 SACRAL NERVE STIMULATION, BY APPLICATION 127
9.5.1 URINE INCONTINENCE 127
9.5.2 FECAL INCONTINENCE 128
9.6 VAGUS NERVE STIMULATION 128
9.6.1 VAGUS NERVE STIMULATION, BY TYPE 129
9.6.1.1 BATTERY 130
9.6.1.2 LEAD 130
9.6.2 VAGUS NERVE STIMULATION, BY APPLICATION 130
9.6.2.1 EPILEPSY 130
9.6.2.2 OTHERS 130
9.7 GASTRIC ELECTRICAL STIMULATION 130
9.7.1 GASTRIC ELECTRICAL STIMULATION, BY TYPE 131
9.7.1.1 BATTERY 132
9.7.1.2 LEAD 132
9.7.2 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 132
9.7.2.1 GASTROPARESIS 133
9.7.2.2 OTHERS 133
10 MIDDLE EAST & AFRICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL 134
10.1 OVERVIEW 135
10.2 DIRECT TENDER 137
10.3 THIRD PARTY PROVIDER 138
11 MIDDLE EAST & AFRICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION 140
11.1 MIDDLE EAST AND AFRICA 141
11.1.1 SOUTH AFRICA 154
11.1.2 U.A.E. 162
11.1.3 EGYPT 170
11.1.4 SAUDI ARABIA 178
11.1.5 ISRAEL 186
11.1.6 REST OF MIDDLE EAST AND AFRICA 194
12 MIDDLE EAST & AFRICA INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY LANDSCAPE 195
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 195
13 SWOT ANALYSIS 196
14 COMPANY PROFILE 197
14.1 MEDTRONIC (2021) 197
14.1.1 COMPANY SNAPSHOT 197
14.1.2 REVENUE ANALYSIS 197
14.1.3 COMPANY SHARE ANALYSIS 198
14.1.4 PRODUCT PORTFOLIO 198
14.1.5 RECENT DEVELOPMENTS 199
14.2 BOSTON SCIENTIFIC CORPORATION (2021) 200
14.2.1 COMPANY SNAPSHOT 200
14.2.2 REVENUE ANALYSIS 201
14.2.3 COMPANY SHARE ANALYSIS 201
14.2.4 PRODUCT PORTFOLIO 202
14.2.5 RECENT DEVELOPMENTS 202
14.3 ABBOTT (2021) 204
14.3.1 COMPANY SNAPSHOT 204
14.3.2 REVENUE ANALYSIS 204
14.3.3 COMPANY SHARE ANALYSIS 205
14.3.4 PRODUCT PORTFOLIO 205
14.3.5 RECENT DEVELOPMENTS 206
14.4 LIVANOVA PLC (2021) 207
14.4.1 COMPANY SNAPSHOT 207
14.4.2 REVENUE ANALYSIS 207
14.4.3 COMPANY SHARE ANALYSIS 208
14.4.4 PRODUCT PORTFOLIO 208
14.4.5 RECENT DEVELOPMENTS 208
14.5 NEVRO CORP. (2021) 210
14.5.1 COMPANY SNAPSHOT 210
14.5.2 REVENUE ANALYSIS 210
14.5.3 COMPANY SHARE ANALYSIS 211
14.5.4 PRODUCT PORTFOLIO 211
14.5.5 RECENT DEVELOPMENTS 212
14.6 AXONICS, INC. 213
14.6.1 COMPANY SNAPSHOT 213
14.6.2 REVENUE ANALYSIS 213
14.6.3 PRODUCT PORTFOLIO 214
14.6.4 RECENT DEVELOPMENTS 214
14.7 ALEVA NEUROTHERAPEUTICS 215
14.7.1 COMPANY SNAPSHOT 215
14.7.2 PRODUCT PORTFOLIO 215
14.7.3 RECENT DEVELOPMENTS 215
14.8 BIONIC VISION TECHNOLOGIES. 216
14.8.1 COMPANY SNAPSHOT 216
14.8.2 PRODUCT PORTFOLIO 216
14.8.3 RECENT DEVELOPMENTS 216
14.9 BLUEWIND MEDICAL 217
14.9.1 COMPANY SNAPSHOT 217
14.9.2 PRODUCT PORTFOLIO 217
14.9.3 RECENT DEVELOPMENTS 217
14.10 BIOINDUCTION 218
14.10.1 COMPANY SNAPSHOT 218
14.10.2 PRODUCT PORTFOLIO 218
14.10.3 RECENT DEVELOPMENT 218
14.11 CIRTEC 219
14.11.1 COMPANY SNAPSHOT 219
14.11.2 PRODUCT PORTFOLIO 219
14.11.3 RECENT DEVELOPMENTS 220
14.12 FINETECH MEDICAL 221
14.12.1 COMPANY SNAPSHOT 221
14.12.2 PRODUCT PORTFOLIO 221
14.12.3 RECENT DEVELOPMENTS 221
14.13 GIMER MEDICAL 222
14.13.1 COMPANY SNAPSHOT 222
14.13.2 PRODUCT PORTFOLIO 222
14.13.3 RECENT DEVELOPMENTS 222
14.14 INSPIRE MEDICAL SYSTEMS, INC. 223
14.14.1 COMPANY SNAPSHOT 223
14.14.2 REVENUE ANALYSIS 223
14.14.3 PRODUCT PORTFOLIO 224
14.14.4 RECENT DEVELOPMENTS 224
14.15 INTEGER HOLDINGS CORPORATION 225
14.15.1 COMPANY SNAPSHOT 225
14.15.2 REVENUE ANALYSIS 225
14.15.3 PRODUCT PORTFOLIO 226
14.15.4 RECENT DEVELOPMENT 226
14.16 INBRAIN NEUROELECTRONICS 227
14.16.1 COMPANY SNAPSHOT 227
14.16.2 PRODUCT PORTFOLIO 227
14.16.3 RECENT DEVELOPMENT 227
14.17 MAINSTAY MEDICAL 228
14.17.1 COMPANY SNAPSHOT 228
14.17.2 REVENUE ANALYSIS 228
14.17.3 PRODUCT PORTFOLIO 229
14.17.4 RECENT DEVELOPMENTS 229
14.18 MICROSEMI (A WHOLLY OWNDED SUBSIDIARY OF MICROCHIP TECHNOLOGY INC.) 230
14.18.1 COMPANY SNAPSHOT 230
14.18.2 REVENUE ANALYSIS 230
14.18.3 PRODUCT PORTFOLIO 231
14.18.4 RECENT DEVELOPMENTS 231
14.19 MICROTRANSPONDER INC 232
14.19.1 COMPANY SNAPSHOT 232
14.19.2 PRODUCT PORTFOLIO 232
14.19.3 RECENT DEVELOPMENT 232
14.20 MICRO-LEADS 233
14.20.1 COMPANY SNAPSHOT 233
14.20.2 PRODUCT PORTFOLIO 233
14.20.3 RECENT DEVELOPMENT 233
14.21 NALU MEDICAL, INC 234
14.21.1 COMPANY SNAPSHOT 234
14.21.2 PRODUCT PORTFOLIO 234
14.21.3 RECENT DEVELOPMENT 234
14.22 NEURONANO AB 235
14.22.1 COMPANY SNAPSHOT 235
14.22.2 PRODUCT PORTFOLIO 235
14.22.3 RECENT DEVELOPMENTS 235
14.23 NEURIMPULSE S.R.L. 236
14.23.1 COMPANY SNAPSHOT 236
14.23.2 PRODUCT PORTFOLIO 236
14.23.3 RECENT DEVELOPMENTS 236
14.24 NEWRONIKA S.P.A. 237
14.24.1 COMPANY SNAPSHOT 237
14.24.2 PRODUCT PORTFOLIO 237
14.24.3 RECENT DEVELOPMENTS 237
14.25 OPTOGENTECH GMBH. 238
14.25.1 COMPANY SNAPSHOT 238
14.25.2 PRODUCT PORTFOLIO 238
14.25.3 RECENT DEVELOPMENTS 238
14.26 ONWARD 239
14.26.1 COMPANY SNAPSHOT 239
14.26.2 PRODUCT PORTFOLIO 239
14.26.3 RECENT DEVELOPMENT 239
14.27 STIMWAVE LLC (2021) 240
14.27.1 COMPANY SNAPSHOT 240
14.27.2 PRODUCT PORTFOLIO 240
14.27.3 RECENT DEVELOPMENTS 240
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
